Effect of a single dose (10 mg) of zolpidem on visual and spectral analysis of sleep in young poor sleepers

Zolpidem reduces hippocampal neuronal activity in freely behaving mice: a large scale calcium imaging study with miniaturized fluorescence microscope

Therapeutic drugs for cognitive and psychiatric disorders are often characterized by their molecular mechanism of action. Here we demonstrate a new approach to elucidate drug action on large-scale neuronal activity by tracking somatic calcium dynamics in hundreds of CA1 hippocampal neurons of pharmacologically manipulated behaving mice. We used an adeno-associated viral vector to express the calcium sensor GCaMP3 in CA1 pyramidal cells under control of the CaMKII promoter and a miniaturized microscope to observe cellular dynamics. We visualized these dynamics with and without a systemic administration of Zolpidem, a GABAA agonist that is the most commonly prescribed drug for the treatment of insomnia in the United States. Despite growing concerns about the potential adverse effects of Zolpidem on memory and cognition, it remained unclear whether Zolpidem alters neuronal activity in the hippocampus, a brain area critical for cognition and memory. Zolpidem, when delivered at a dose known to induce and prolong sleep, strongly suppressed CA1 calcium signaling. The rate of calcium transients after Zolpidem administration was significantly lower compared to vehicle treatment. To factor out the contribution of changes in locomotor or physiological conditions following Zolpidem treatment, we compared the cellular activity across comparable epochs matched by locomotor and physiological assessments. This analysis revealed significantly depressive effects of Zolpidem regardless of the animal's state. Individual hippocampal CA1 pyramidal cells differed in their responses to Zolpidem with the majority (∼ 65%) significantly decreasing the rate of calcium transients, and a small subset (3%) showing an unexpected and significant increase. By linking molecular mechanisms with the dynamics of neural circuitry and behavioral states, this approach has the potential to contribute substantially to the development of new therapeutics for the treatment of CNS disorders.

General safety profile of zolpidem: safety in elderly, overdose and rebound effects

The different aspects of general safety of zolpidem are reviewed after analysing the safety data obtained in adults as well as in elderly patients. The low incidence of reported adverse events during the first three years of utilisation of zolpidem have corroborated the results of the clinical studies. The most frequent adverse effects are central nervous system (CNS) related but they can be largely prevented by respecting the recommended doses and prescription rules. In cases of acute overdoses, no severe complications have been attributed to zolpidem taken alone. In most of the studies carried out within the recommended treatment duration, abrupt treatment discontinuation was not associated with clinically significant rebound insomnia, and the available pre-clinical and clinical data indicate that the risk of abuse or dependence is minimal when prescribed according to the recommended doses of 10 mg in adults and 5 mg in elderly. Thus, with now well-established arguments on a large patient basis going in the same direction, the safety of zolpidem can authorise and justify its wide prescription in the short-term treatment of insomnia.

Sleep EEG predictors and correlates of the response to cognitive behavioral therapy for insomnia

STUDY OBJECTIVES

Determine the relationship of non-rapid eye movement (NREM) electroencephalographic (EEG) spectral measures and the response to cognitive behavioral therapy (CBT) in primary insomnia (PI).

DESIGN

Patients with PI were randomly assigned to CBT or a placebo intervention (PC). Ambulatory polysomnography was performed before and after treatment.

SETTING

University medical center sleep laboratory.

PARTICIPANTS

Thirty PI patients with sleep maintenance difficulty evident in subjective sleep measures.

INTERVENTIONS

CBT and PC.

RESULTS

CBT led to a more rapid decline in EEG delta power over the night, compared with PC. This change was associated with subjective improvement in response to CBT. Furthermore, lower pretreatment peak EEG delta power in the first NREM cycle and a more gradual decline in delta power predicted a better response to CBT. Increased wake time during the day produced by CBT was correlated with an increase in the steepness of the slope of EEG delta power and subjective improvement. Traditional polysomnography measures were associated with the subjective CBT response to a greater degree among patients whose total sleep time estimates better approximated polysomnography-derived total sleep time. In contrast, changes in all-night averaged NREM EEG spectral indices were more strongly related to subjective improvement in individuals who underestimated total sleep time to a greater extent.

CONCLUSIONS

CBT led to a more rapid decline in EEG delta power over the night. This change is linked to the therapeutic effect of CBT, which appears to occur in conjunction with an increase in homeostatic sleep drive. Traditional polysomnography indices and all-night averaged NREM EEG measures appear to be related to subjective improvements with CBT in subsets of patients with PI.

Automatic analysis of single-channel sleep EEG: validation in healthy individuals

STUDY OBJECTIVE

To assess the performance of automatic sleep scoring software (ASEEGA) based on a single EEG channel comparatively with manual scoring (2 experts) of conventional full polysomnograms.

DESIGN

Polysomnograms from 15 healthy individuals were scored by 2 independent experts using conventional R&K rules. The results were compared to those of ASEEGA scoring on an epoch-by-epoch basis.

SETTING

Sleep laboratory in the physiology department of a teaching hospital.

PARTICIPANTS

Fifteen healthy volunteers.

MEASUREMENTS AND RESULTS

The epoch-by-epoch comparison was based on classifying into 2 states (wake/sleep), 3 states (wake/REM/ NREM), 4 states (wake/REM/stages 1-2/SWS), or 5 states (wake/REM/ stage 1/stage 2/SWS). The obtained overall agreements, as quantified by the kappa coefficient, were 0.82, 0.81, 0.75, and 0.72, respectively. Furthermore, obtained agreements between ASEEGA and the expert consensual scoring were 96.0%, 92.1%, 84.9%, and 82.9%, respectively. Finally, when classifying into 5 states, the sensitivity and positive predictive value of ASEEGA regarding wakefulness were 82.5% and 89.7%, respectively. Similarly, sensitivity and positive predictive value regarding REM state were 83.0% and 89.1%.

CONCLUSIONS

Our results establish the face validity and convergent validity of ASEEGA for single-channel sleep analysis in healthy individuals. ASEEGA appears as a good candidate for diagnostic aid and automatic ambulant scoring.

Ceiling and floor effects in sleep research

Ceiling and floor effects dictate that the efficacy of sleep-promoting stimuli should be proportional to the degree of pre-stimulus sleep impairment. This review addressed CF effects in polysomnographic research involving hypnotic drugs and exercise. Correlations of placebo/baseline levels of sleep with changes in sleep following hypnotic or exercise treatment were assessed across both literatures. CF effects were further addressed by comparing sleep-promoting effects of hypnotics vs exercise, after ANCOVA control for substantial baseline differences reported in studies of these stimuli. Significant correlations between placebo-baseline levels and sleep changes were observed following both hypnotic and exercise stimuli. Indeed, approximately 60% of the variance in improvement in sleep latency (SOL), wakefulness after sleep onset (WASO) and total sleep time (TST) following hypnotic treatment was associated with differences in baseline levels. ANCOVAs revealed significantly greater decreases in SOL and WASO following hypnotics compared with exercise. However, no significant difference between stimuli was found for TST, and exercise elicited a significantly greater increase in slow wave sleep. Similar results were found when a comparison between hypnotics and exercise was limited to good sleepers. The results show powerful CF influences on sleep responses to hypnotics and exercise and suggest a need for comparing these treatments in poor sleepers.

Slow (0.7-2 Hz) and fast (2-4 Hz) delta components are differently correlated to theta, alpha and beta frequency bands during NREM sleep

OBJECTIVES

Spectral power of 40 all-night sleep EEGs (Cz-Pz bipolar lead) recorded in 20 healthy young subjects was calculated after normalization on 30-s consecutive epochs by means of an autocorrelation method based on a 15-order autoregressive model.

METHODS

The spectral parameters were calculated for the 7 main EEG bands: slow delta (0.7-2 Hz); fast delta (2-4 Hz); theta (4-8 Hz); alpha (8-12 Hz); sigma (12-16 Hz); beta1 (16-35 Hz); and beta 2 (>35 Hz).

RESULTS

Strong negative correlations were found between power in the fast delta and either the alpha or the beta bands and between slow delta and theta bands, whereas the two delta bands showed little correlation with each other.

CONCLUSION

The possibility that theses different relationships of slow and fast delta components with other frequency bands might reflect the neocortical or the thalamocortical origin of the delta waves is discussed.

Comparison of the effects of zolpidem and triazolam on nocturnal sleep and sleep latency in the morning: a cross-over study in healthy young volunteers

1. Zolpidem (ZPD, 10 mg) was directly compared with triazolam (TRZ, 0.25 mg), a benzodiazepine hypnotic of a short action comparable to ZPD. The compounds were given to healthy young subjects for three nights, in a crossover design. 2. Polysomnographic data of three 150-min sections of the nights as well as the whole nights were analyzed, to clearly detect the proper effects of the very short acting hypnotics, which might be missed in the analysis of whole night. 3. Time courses were significantly different between the two compounds in the ratios (%) of stage wake (SW), stage 2 (S2), slow wave sleep (SWS) and stage REM (SR). 4. Compared to the baseline, SWS was increased by ZPD on the first night, not by TRZ. The separate analysis of the three 150-min sections revealed an increase of SWS during the first 150-min of the ZPD night, suggesting a proper action of ZPD to augment SWS. An increase of S2 and a decrease of SR were caused by TRZ, not by ZPD. However, the separate analysis indicated that ZPD might reduce SR during the first 150-min, which was cancelled by a subsequent rebound increase in the whole night analysis. 5. During the withdrawal period, TRZ, not ZPD, increased SW and SR with worsening of mood in the morning. ZPD did not affect sleep latency in the morning, while TRZ caused a trend of the reduction.

Zolpidem and sleep deprivation: different effect on EEG power spectra

To study the role of GABA-ergic mechanisms in sleep regulation, the combined action of 40 h sleep deprivation and either 20 mg zolpidem or placebo on the sleep electroencephalogram (EEG) were investigated by quantitative EEG analysis in eight young men who participated in a positron emission tomography study. Compared with baseline, sleep deprivation increased low-frequency (1.25-7.0 Hz) EEG power in non-rapid eye movement (NREM) sleep in the placebo night. After administration of zolpidem, power in the 3.75-10.0 Hz range and 14. 25-16.0 Hz band was reduced. The largest decrease was observed in the theta band. Comparison with placebo revealed that zolpidem attenuated power in the entire 1.75-11.0 Hz range. The plasma concentration of zolpidem at 4.5 h after intake showed a positive correlation with the drug-induced difference in power from placebo in the 14.25-16.0 Hz band. Regional EEG analysis based on bipolar derivations along the antero-posterior axis disclosed, for NREM sleep, a drug-induced posterior shift of power in the frequency range of 7.75-9.75 Hz. Zolpidem did not affect rapid eye movemnt sleep spectra. We conclude that sleep deprivation and agonistic modulation of GABAA receptors have separate and additive effects on power spectra and that their effects are mediated by different neurophysiological mechanisms.

The safety and tolerability of zolpidem--an update

Zolpidem belongs to a new class of hypnotic agents, chemically distinct from the pre-existing ones, and has a unique neuropharmacological profile. It induces sedative/hypnotic effects in rodents at doses much lower than those for anticonvulsant and myorelaxant activities. Clinically, zolpidem is indicated for the short term treatment of insomnia. It has a short half-life (2.4h), with no active metabolite, and does not accumulate during repeated administration. The pharmacokinetic profile associated with the absence of active metabolites is consistent with the short duration of action and absence of residual effects that have been observed. Polysomnographic experience indicates that zolpidem induces a sleep pattern which is similar to that of physiological sleep, and which produces either no or only minimal effects on sleep architecture after abrupt discontinuation. Aspects of the general safety of zolpidem have been studied in data obtained from healthy volunteers and patients, both adult and elderly, during its clinical development and in post-marketing experience. Zolpidem appears to be well-tolerated in adults and in the elderly, when administered in accordance with prescribing instructions. The available data indicate that, in these circumstances, the risk of abuse or dependence is minimal.

Polysomnographic effects of hypnotic drugs. A review

This review aims at providing a critical assessment of the effects of the most widely used benzodiazepine (flurazepam, flunitrazepam, temazepam, triazolam) and non-benzodiazepine (zopiclone and zolpidem) hypnotic drugs, based on the recording of polysomnographic variables. In the light of newly acquired neurophysiological data on the microstructure of sleep, this paper reconsiders the problem of insomnia and the current ideas on polysomnography and hypnotic drugs.